



Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization
4-7 April 2022
Virtual Meeting
Final Agenda

Day 1: Monday, 4 April 2022

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
10:00	Closed SAGE meeting	Preparation of the sessions of the day.	1h
11:00	Break	Break	15 min.
11:15	Opening and welcome – introduction of participants K. O'BRIEN, IVB Director WHO. A. CRAVIOTO, SAGE chair J. HOMBACH, SAGE secretariat WHO.	Opening of the Plenary Meeting	15 min.
11:30	Global and Regional Reports – Session 1 Report from the Director of IVB. K. O'BRIEN, WHO. 20 min. Update from Gavi. S. BERKLEY, GAVI. 10 min. Reports from the Regions – including impact of the COVID-19 pandemic and COVID-19 vaccination on immunization services. WHO. 1h Discussion. 1h	FOR INFORMATION	2h 30 min.
14:00	Break	Break	30 min.
14:30	IA2030 deep dive: catch-up vaccination – Session 2 Impact of the COVID-19 pandemic and pathway to recovery through Immunization Agenda 2030. N. MACDONALD and F. OLAYINKA, SAGE members. 10 min. Country presentation 1. P. HALDAR, Ministry of Health and Family Welfare. India. 10 min. Country presentation 2. J. L. DIAZ ORTEGA, MoH Mexico. 10 min. Guiding principles for recovering, building resiliency, and strengthening of immunization in 2022 and beyond. S. SODHA, WHO. 15 min. Discussion. 65 min.	FOR RECOMMENDATION This session will discuss the importance and need to urgently recover immunization programmes, build their resiliency, and strengthen for the long term. SAGE will be asked to review and consider for endorsement the importance for countries to develop and implement strategies to urgently bridge immunity gaps, recover immunization programmes, and build resiliency against future disruptions and health system strains. SAGE is also asked to provide input and endorse "Guiding Principles for recovering, building resiliency, and strengthening of immunization in 2022 and beyond".	1h 50 min.
16:20	End of the day		

Day 2: Tuesday 5 April 2022

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
10:00	Closed SAGE meeting	Preparation of the sessions of the day. Recap of day 1. Other important discussion items.	1h
11:00	Break	Break	15 min.
11:15	Hepatitis A – Session 3	FOR RECOMMENDATION	2h
	<p>Introduction of the session, objectives and critical questions R. AGGARWAL, SAGE member and WG chair. 5 min.</p> <p>Overview on disease, global epidemiology and available vaccine products hepatitis A disease. K. MELLOU, SAGE Hepatitis A WG member, T. CERNUSCHI, WHO. 10 min.</p> <p>Main outcomes of the systematic review of evidence. N. WALSH, J. TORRES, WHO secretariat – contractors. 20 min.</p> <p>Presentation of the GRADE/ ETR tables. N. NELSON. SAGE Hepatitis A WG member. 10 min.</p> <p>Question and answers Discussion by SAGE members. 25 min.</p> <p>Draft recommendations. R. AGGARWAL, SAGE member and WG chair. 15 min</p> <p>Discussion by SAGE 30 min.</p> <p>Wrap up. R. AGGARWAL, SAGE member. 5 min</p>	<p>The purpose of this session is to update the SAGE recommendations on the use of hepatitis A vaccine (2012 Vaccine position paper). This update will be based on :</p> <ul style="list-style-type: none"> - the accrued data on the global prevalence and burden of disease caused by hepatitis A virus infection, including outbreaks since 2012. - the review of latest available data on efficacy, effectiveness, duration of protection, schedules, safety, and cost-effectiveness of internationally available hepatitis A vaccines, considering all dosing and schedules in particular single dose schedules of inactivated vaccine. <p>The outcome will be a 2022 update of the Hepatitis A vaccine position paper.</p>	
13:15	Break	Break	30 min.
13:45	COVID-19 vaccines – Session 4		2h 30 min.
	<p>Introduction. H. NOHYNEK, SAGE member. 5 min.</p> <p><i>Vaccine product specific recommendations: Cansino</i></p> <p>Company presentation. Cansino. 20 min.</p> <p>Questions and answers. 15 min.</p> <p>Evidence review. WHO. 20 min.</p> <p>Presentation of draft recommendations including discussion. H. NOHYNEK, SAGE member. 30 min.</p>	FOR RECOMMENDATION	
	<p><i>Infection and vaccination induced immunity</i></p> <p>Seroprevalence studies. I. BERGERI, WHO. 5 min.</p> <p>Immunological findings. D. GOLDBLATT, University College London. 5 min.</p> <p>Vaccine effectiveness and hybrid immunity. M. PATEL, WHO secretariat. 5 min.</p> <p>Insights from epidemiological analysis and modelling. N. FERGUSON, Imperial College London. 15 min.</p> <p>Discussion. A. CRAVIOTO, SAGE chair. 20 min.</p>	FOR DISCUSSION	
16:15	End of the day		

Day 3: Wednesday 6 April 2022

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
10:00	Closed SAGE meeting	Preparation of the sessions of the day. Recap of day 2. Other important discussion items.	1h
11:00	Break	Break	15 min.
11:15	Typhoid update – Session 5	FOR INFORMATION	1h 30 min.
	<p>Introduction and framing. K. MULHOLLAND, SAGE member. 5 min.</p> <p>Updates on global burden and AMR. J. CRUMP, U. of Otago. 10 min.</p> <p>TCV evidence emerging from TyVAC and other studies (incl data on efficacy/effectiveness, immunogenicity, safety, co-admin, use in special populations). K. NEUZIL, SAGE member. 25 min.</p> <p>Discussion. 15 min.</p> <p>Update on TCV pipeline and evidence to inform future SAGE sessions. M. CAREY, U. of Cambridge. 10 min.</p> <p>Early TCV introduction experiences. J. WALLDORF, WHO. 10 min.</p> <p>Discussion. 15 min.</p>	<p>Update on new evidence from prequalified typhoid conjugate vaccines (TCVs) and late-stage vaccine candidates on vaccine efficacy and effectiveness, immunogenicity and safety; data from special populations; data from older age groups; tolerability and non-interference in immune responses with routine EPI vaccines.</p> <p>The data available support the current TCV policy recommendations and a revision is not being considered at this time. However, SAGE is being requested to make a statement in its report on the new evidence from prequalified TCVs (particularly on vaccine efficacy), to inform country decision making for ongoing TCV introductions.</p>	
12:45	Break	Break	30 min.
13:15	HPV – Session 6	FOR RECOMMENDATION	2h 30 min
	<p>Session introduction and key questions. R AGGARWAL. SAGE member and WG chair. 5 min.</p> <p>Update on progress of HPV vaccine introduction and reaching the 2030 target of 90% coverage. P. BLOEM, WHO. 10 min.</p> <p>Global market study on HPV vaccines, 2022 Update. T. CERNUSHI. WHO. 10 min.</p> <p>Evidence on single-dose HPV vaccine schedules to inform decision making on reduced schedules. L. MARKOVITZ, SAGE WG member. 10 min</p> <p>Systematic review of evidence on HPV vaccine. N. HENSCHKE, Cochrane Response. 10 min.</p> <p>Modelling evidence on the impact of 1-dose strategies. M. BRISSON, Laval University. 10 min.</p> <p>Discussion on the evidence. 45 min.</p> <p>Conclusions and proposed recommendations by SAGE Working Group. R AGGARWAL, SAGE member and WG chair. 10 min.</p> <p>Discussion on the recommendations. 40 min.</p>	<p>Present SAGE with updated evidence on single dose HPV vaccination schedule, and modelling of impact of HPV immunization schedules and strategies in the context of supply constraint.</p> <p>SAGE is requested to consider the following questions:</p> <ul style="list-style-type: none"> • What is the current HPV vaccine uptake and what are the main barriers for access to HPV vaccines? • What does current evidence show on the immunogenicity and efficacy of a single dose of HPV vaccine and different intervals between the first and second doses of HPV vaccine? And what are the risks of bias of these studies? • What are the potential demand scenarios and the supply of HPV vaccines (short and mid-term outlook) and what could the enhanced HPV vaccine supply allocation be? • In light of the above conclusions and evidence, how should HPV vaccine introduction be prioritized with respect to impact and feasibility? 	
15:45	End of the day		

Day 4: Thursday 7 April 2022

Time	Session	Purpose of session, target outcomes and questions for SAGE	Duration
10:00	Closed SAGE meeting	Preparation of the sessions of the day. Recap of day 3. Other important discussion items.	1h
11:00	Break	Break	15 min.
11:15	Polio – Session 7	FOR RECOMMENDATION	1h 45 min.
	<p>Session overview by I. JANI, SAGE Member. 5 min.</p> <p>Update from the Global Polio Eradication Initiative. A. O'LEARY, WHO. 10 min.</p> <p>Questions: 15 min.</p> <p>OPV Cessation Planning. O. MACH, WHO. 10 min.</p> <p>Questions: 10 min.</p> <p>Update on nOPV2: assessment of safety data and initial field efficacy evaluation. G. MACKLIN, A. BANDYOPADHYAY, WHO/BMGF. 15 min.</p> <p>Questions: 10 min.</p> <p>Report from SAGE Polio Working Group including remarks on OPV2 use in the European Region. I. JANI, SAGE Member. 10 min.</p> <p>Discussion: 20 min.</p>	<p>SAGE will be informed on the current status of the polio eradication program and of the implementation of the new polio eradication strategy. SAGE will be updated on the updated safety data, and initial field efficacy evaluation of nOPV2.</p> <p>SAGE will be asked to review and consider for endorsement:</p> <ul style="list-style-type: none"> • WG's recommendation on initial planning for OPV cessation • WG's recommendation on literature review on use of OPV2 vaccines 	
13:00	End of SAGE Plenary meeting		
13:00	Break	Break	30 min.
13:30	Closed SAGE session	Meeting wrap up.	2h
15:30	End of final closed meeting		